Key result
IV vernakalant achieves ~87% higher odds of rapid cardioversion for acute AF versus IV procainamide.
Why the study?
Does IV vernakalant improve conversion to sinus rhythm in patients with acute atrial fibrillation compared to IV procainamide?
RCT (n=350)
Open-label
1:1
Yes
Does IV vernakalant improve conversion to sinus rhythm in patients with acute atrial fibrillation compared to IV procainamide?
IV vernakalant is a safe and superior alternative to procainamide for rapid and effective pharmacologic cardioversion of acute AF in the ED, particularly in patients <70 years old.
Answers are grounded in this paper and cite their sources.
May favor vernakalant for acute AF cardioversion; leaves open confirmation in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mandal et al. (2026) conducted an RCT in Acute atrial fibrillation (n=350). IV vernakalant vs. IV procainamide was evaluated on Conversion to sinus rhythm within 30 min of drug infusion completion (OR 1.87, 95% CI 1.2 to 2.9, p=0.006). IV vernakalant was superior to IV procainamide for rapid cardioversion of acute atrial fibrillation, achieving a higher conversion rate to sinus rhythm.
Synapse has enriched 10 related papers. Consider them for comparative context: